TY - JOUR
T1 - Effects of acute beta-adrenoceptor blockade with metoprolol on the renal response to dopamine in normal humans
AU - Olsen, Niels Vidiendal
AU - Lang-Jensen, T
AU - Hansen, J M
AU - Plum, I
AU - Thomsen, J K
AU - Strandgaard, S
AU - Leyssac, P P
PY - 1994/4
Y1 - 1994/4
N2 - The present study investigated the contribution of adrenergic beta 1-receptor stimulation to the cardiovascular and renal effects of low-dose dopamine in eight normal, water-loaded humans. Metoprolol (100 mg) or placebo was administered orally at 08.00 h in a randomized, double-blind fashion on two different days. Renal clearance studies were performed during a 1 h baseline period, two 1 h periods with dopamine infusion (3 micrograms kg-1 min-1), and a 1 h recovery period. Cardiac output was measured by an ultrasonic Doppler method, and lithium clearance (CLLi) was used to estimate proximal tubular outflow. Baseline values of heart rate, systolic pressure and mean arterial pressure decreased with metoprolol compared with placebo, but cardiac output, effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were not significantly changed. Metoprolol significantly decreased baseline CLLi and sodium clearance (CLNa) by 19% (P <0.01) and 34% (P <0.01), respectively. Metoprolol blunted the dopamine-induced increases in heart rate and systolic pressure, but cardiac output increased to the same extent on both study days by 26% (placebo, P <0.05) and by 31% (metoprolol, P <0.01), respectively. With and without metoprolol, dopamine did not significantly change GFR, and the percentage increases in ERPF were similar on the two study days (40% (P <0.001) and 42% (P <0.001), respectively). Dopamine increased CLLi and CLNa by 31% (P <0.01) and 114% (P <0.01), respectively, with placebo, and by 36% (P <0.01) and 114% (P <0.01), respectively, with metoprolol. Values during infusion remained significantly lower with metoprolol compared with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
AB - The present study investigated the contribution of adrenergic beta 1-receptor stimulation to the cardiovascular and renal effects of low-dose dopamine in eight normal, water-loaded humans. Metoprolol (100 mg) or placebo was administered orally at 08.00 h in a randomized, double-blind fashion on two different days. Renal clearance studies were performed during a 1 h baseline period, two 1 h periods with dopamine infusion (3 micrograms kg-1 min-1), and a 1 h recovery period. Cardiac output was measured by an ultrasonic Doppler method, and lithium clearance (CLLi) was used to estimate proximal tubular outflow. Baseline values of heart rate, systolic pressure and mean arterial pressure decreased with metoprolol compared with placebo, but cardiac output, effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were not significantly changed. Metoprolol significantly decreased baseline CLLi and sodium clearance (CLNa) by 19% (P <0.01) and 34% (P <0.01), respectively. Metoprolol blunted the dopamine-induced increases in heart rate and systolic pressure, but cardiac output increased to the same extent on both study days by 26% (placebo, P <0.05) and by 31% (metoprolol, P <0.01), respectively. With and without metoprolol, dopamine did not significantly change GFR, and the percentage increases in ERPF were similar on the two study days (40% (P <0.001) and 42% (P <0.001), respectively). Dopamine increased CLLi and CLNa by 31% (P <0.01) and 114% (P <0.01), respectively, with placebo, and by 36% (P <0.01) and 114% (P <0.01), respectively, with metoprolol. Values during infusion remained significantly lower with metoprolol compared with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
KW - Adult
KW - Dopamine
KW - Dopamine Antagonists
KW - Double-Blind Method
KW - Female
KW - Glomerular Filtration Rate
KW - Hemodynamics
KW - Humans
KW - Infusions, Intravenous
KW - Kidney
KW - Lithium
KW - Male
KW - Metabolic Clearance Rate
KW - Metoprolol
KW - Receptors, Adrenergic, beta
KW - Renal Circulation
KW - Sodium
M3 - Journal article
C2 - 8018456
SN - 0264-3774
VL - 37
SP - 347
EP - 353
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
IS - 4
ER -